Letter From The Editor

Each week there seem to be articles, studies, and clinical treatises that draw a link between diabetes and cardiovascular disease. If you look through all these documents, the benchmark for measurement always seems to be A1c. However, if you were to take a look at this week’s Homerun Slides from …

There is some interesting research going on at the University of Missouri about high protein breakfasts that actually delivers a profound message for a reason to use the medication Cycloset. Researchers found that eating breakfast, particularly meals rich in protein, increases young adults’ levels of dopamine which may reduce food …

We have added five totally new classes of non-insulin medications for the treatment of diabetes and so sometimes the reasons to even try insulin make no sense to many of us. However, when we identify patients that have severe cases of glucotoxicity and/or lipotoxicity we often find that they will …

This past weekend I was in Lexington, Kentucky to visit my father and sisters. While I was there, I saw a commercial for a heart institute and they mentioned that heart disease was the number one killer in America today. I would have to agree that many people die of …

Two years ago the Affordable Care Act brought about the beginning of ACO’s (accountable care organizations). These organizations were created to bring quality of care into play for patients and to reward the best care providers with financial incentives. CMS wanted to prove the value of these ACO’s and so …

When we were kids, we used to play a game called Red Light/Green Light, and the goal was to sneak up on the "it" person without them catching your moves. In this week’s Homerun Slides series, we bring you a way to use this game to help your patients get …

This week we find that a lot of information is coming out the EASD meeting in Vienna, and much of it has to do with the use of pump therapy in patient care. There is also a great article that dispels any concerns you may have about starting your patients …

The FDA works really hard these days to come up with new brand names that will lessen the chance of drug choice confusion. Often times we wonder how they can come up with these names and what meaning they have. With this in mind, this week’s Diabetes Disaster Averted points …

For the past 18 months we have been providing you with a monthly newsletter with special features focused on GLP-1 analogs. These newsletters have provided information beginning with the first discovery of GLP-1 and GIP in the body and how they worked to control glucose levels, and have included practice …

There has been a lot going on with drugs in the GLP-1 agonist class over the past few months. First we added Tanzeum (albiglutide) as a once-a-week drug. Then the new Bydureon pen was introduced, and finally, Lilly got their once-weekly auto-injector pen product Trulicity (dulaglutide) approved by the FDA. …